Parameter
| Biomarker | CD20 | Full name | Cluster of differentiation 20 | Molecular Type | Protein |
|---|---|---|---|---|---|
| Molecular Formula | / | Molecular Weight | / | Core Functional Dimensions | Auxiliary diagnosis |
| Disease | Non-Hodgkin Lymphoma (NHL) | Disease Subtypes | / | ||
| Organ | Blood and lymphoid tissue | Test Sample / Technology Platform | Immunohistochemistry (IHC) | ||
| Pathobiological Mechanisms | It is a surface marker of B cells, expressed by normal B cells and some B-cell lymphomas. CD30-positive Hodgkin lymphoma tumor cells often do not express it or exhibit only weakly positive expression. | ||||
| Clinical Availability Status | Clinical validation/Routine application: Primarily used to exclude non-Hodgkin lymphomas of B-cell origin such as diffuse large B-cell lymphoma, and to assist in determining the disease type. | ||||
| Notes and Dynamics | Only a minority of CD30-positive Hodgkin lymphoma cases exhibit weak CD20 positivity, requiring comprehensive evaluation in conjunction with other markers to avoid misdiagnosis based on a single indicator. | ||||